Incyte | INCY - Ebitda

Aktienkurs
99.14
Täglich Wechseln
1.40 1.43%
Monatlich
9.75%
Jährlich
58.22%
Q2 Prognose
92.62




Ebitda Veränderung Datum
Acadia Pharmaceuticals USD 35.76M 447K 2025-09
Agenus USD -10.11M 19.02M 2025-03
Agios Pharmaceuticals USD -120.31M 4.82M 2025-12
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amgen USD 5.14B 775M 2025-12
BioCryst Pharmaceuticals USD 51.7M 30.14M 2025-09
Biogen USD 573.2M 253.7M 2025-12
BioMarin Pharmaceutical USD -24.17M 18.91M 2025-12
Bristol-Myers Squibb USD 4.24B 967M 2025-09
Eli Lilly USD 7.88B 378.1M 2025-09
Exelixis USD 248.93M 28.02M 2025-09
Gilead Sciences USD 3.02B 1.01B 2025-12
Incyte USD 414.5M 92.42M 2025-12
Ionis Pharmaceuticals USD -200.02M 42.89M 2025-12
MacroGenics USD 21.95M 55.39M 2025-09
Merck USD 8.39B 1.97B 2025-09
Moderna USD -790M 582M 2025-12
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 218.4M 28.3M 2025-12
Novartis USD 5.3B 530M 2026-03
Novartis USD 5.84B 235M 2025-09
Pfizer USD 6.08B 351M 2025-09
PTC Therapeutics USD -70.99M 91.62M 2025-12
Puma Biotechnology USD 729K 11.36M 2024-06
Regeneron Pharmaceuticals USD 1.2B 718.4M 2025-12
Sarepta Therapeutics USD -168.03M 294.45M 2025-09
Ultragenyx Pharmaceutical USD -156.79M 65.44M 2025-09
Vertex Pharmaceuticals USD 1.44B 100.4M 2025-09